Platelet inhibitor reduces size of large heart attacks

March 26, 2012, American College of Cardiology

The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.

Angioplasty is performed during a heart attack to restore and reduce the size of the infarct – permanent damage to the heart muscle – which begins within minutes after the onset of chest pain and can continue for up to 12 hours. Too often, however, heart damage is extensive. In some cases the culprits are distal emboli, plaque or blot clots that break off during and lodge in smaller vessels, essentially moving the heart attack downstream to smaller arteries.

Two approaches to prevent this process have been studied extensively with highly conflicting results: (1) delivering high concentrations of abciximab to the blood clot (thrombus) at the site of the lesion, where it keeps platelets from sticking together and causes the clot to collapse, and (2) sucking out the clot through a process called manual aspiration thrombectomy.

"All of the earlier studies have limitations," said Gregg W. Stone, MD, director of cardiovascular research and education, Columbia University Medical Center/New York-Presbyterian Hospital, New York City, and principal investigator of the INFUSE-AMI trial. "To clarify which approach, if any, can reduce the size of the heart attack, we studied only presenting within four hours of symptom onset with a large anterior heart attack, with blockage of the largest heart artery confirmed by cath lab. These are destined to be very large heart attacks, but the patients presented early enough for us to be able to reduce the amount of damage."

INFUSE-AMI used a 2 x 2 factorial design, which isolates the impact of each intervention to maximize the chance of identifying any reduction in heart attack size. The trial, conducted at 37 sites in six countries, screened 6,318 patients and enrolled 452 (7.2 percent). It is a single-blind study in which the operator knew the randomization assignments.

Participants were randomly assigned to one of four arms: (1) aspiration plus abciximab; (2) aspiration without abciximab; (3) no aspiration plus abciximab; and (4) no aspiration or abciximab (control). In the two abciximab arms, a "weeping" balloon catheter delivered the drug right to the site of the lesion, which "invariably has a thrombus," Dr. Stone noted. A catheter was used to aspirate clots. All patients who had angioplasty were given bivalirudin, an anticoagulant that keeps bleeding and mortality low.

The primary efficacy endpoint was heart attack size at 30 days, as measured by cardiac MRI for 382 of 439 surviving patients (87.1 percent). Heart attack size was gauged by calculating infarct size as a percentage of total tissue. Patients in the two abciximab arms had significantly smaller heart attacks than patients in the two no-abciximab arms (median 15.1 percent vs. 17.9 percent). By contrast, aspiration thrombectomy did not decrease heart attack size (17.0 percent) compared with no aspiration (17.3 percent). The aspiration plus abciximab group showed the lowest median heart attack size of 14.7 percent, compared with 17.6 percent for the other three groups combined. Clinically, there were no significant differences among the four groups for any major measures of safety or efficacy at 30 days. Patients will be assessed again at six months and one year.

"This study is important because it demonstrates that in patients with large heart attacks who reach the hospital early, we can reduce the magnitude of heart damage with a bolus of intracoronary abciximab delivered directly to the lesion," Dr. Stone said. "The next step is a larger randomized clinical trial of the two arms of our study that did reduce size, to determine whether this therapy results in an important clinical benefit, as one might expect."

Atrium Medical, manufacturer of the ClearWay RX catheter, funded and participated in design of the study. Dr. Stone serves as a consultant to Atrium Medical and to Medtronic, which manufactures the Export catheter used in the study, to Eli Lilly, distributor of abciximab, and to The Medicines Company, maker of bivalirudin.

This study will be simultaneously published in the Journal of the American Medical Association.

Explore further: Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack

Related Stories

Infusion of drug into the coronary artery may help reduce size of heart damage after heart attack

March 25, 2012
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also ...

Heart attacks are more serious if they occur at certain times of the day

April 28, 2011
People who have a heart attack are likely to be more seriously affected if the attack happens in the morning, reveals research published ahead of print in Heart journal.

New class of platelet blockers proves effective in phase III trial

March 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.